Tegmine Therapeutics
Tegmine Therapeutics is focused on eradicating cancer with revolutionary glycoprotein-targeting antibodies. They utilize their proprietary TegMiner™ platform to discover unique cancer epitopes and develop innovative antibody-based therapies aimed at increasing efficacy and reducing side effects for patients with unmet needs.
Industries
Nr. of Employees
small (1-50)
Tegmine Therapeutics
4104 24th St., Suite PMB 405, San Francisco, CA 94114, USA
Products
Glycoprotein epitope discovery platform
A platform for identifying unique cancer-associated glycoprotein epitopes to enable targeted antibody discovery.
Preclinical antibody therapeutics pipeline
In-house pipeline of antibody-based oncology therapeutic candidates developed from platform-discovered epitopes through preclinical validation.
Glycoprotein epitope discovery platform
A platform for identifying unique cancer-associated glycoprotein epitopes to enable targeted antibody discovery.
Preclinical antibody therapeutics pipeline
In-house pipeline of antibody-based oncology therapeutic candidates developed from platform-discovered epitopes through preclinical validation.
Services
Discovery and optimization of therapeutic antibodies against cancer-associated glycoprotein epitopes.
Early-stage candidate identification and validation for oncology therapeutics including in vitro and in vivo preclinical workflows.
Process development and scale-up activities to support clinical-stage biologic therapeutics.
Data-driven computational analysis and bioinformatics to support target discovery and omics interpretation.
Discovery and optimization of therapeutic antibodies against cancer-associated glycoprotein epitopes.
Early-stage candidate identification and validation for oncology therapeutics including in vitro and in vivo preclinical workflows.
Process development and scale-up activities to support clinical-stage biologic therapeutics.
Data-driven computational analysis and bioinformatics to support target discovery and omics interpretation.
Expertise Areas
- Glycoprotein-targeted therapeutic antibodies
- Epitope discovery for oncology
- Antibody engineering and lead optimization
- Preclinical oncology drug development
Key Technologies
- Glycoprotein epitope discovery platform
- Antibody engineering
- Antibody-drug conjugates (ADC)
- Glycoconjugate vaccine development